Eli Lilly and Company (LLY)
Where Will Eli Lilly Be in 5 Years?
What a difference five years can make. Just look at Eli Lilly (LLY 14.56%).
Here's Why Eli Lilly (NYSE: LLY). Fidelity National (NYSE: FIS) and Diamondback Energy (Nasdaq: FANG) Are Soaring Today
The Dow Jones Industrial Average is tumbling by another 440 points in midday trading today, as President Trump criticized Federal Reserve chairman Jerome Powell's position, but the fact he is not trying to fire him heartened enough investors that the S&P 500 has bounced back into positive territory.
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.
These 2 Dividend Giants Are at 52-Week Lows. Time to Buy?
One man's trash may be another man's treasure, but dumpster diving when investing carries risks.
Eli Lilly shares surge on strong trial results for weight-loss pill
Eli Lilly and Co (NYSE:LLY) shares jumped 12% in premarket trading on Thursday after the drugmaker said its experimental weight-loss pill, orforglipron, succeeded in a late-stage trial in patients with type 2 diabetes, showing promise as a potential rival to injectable treatments like Ozempic. The once-daily oral drug significantly reduced blood sugar levels and body weight in the Phase 3 trial, marking a milestone as the first oral GLP-1 receptor agonist to reach this stage without requiring food or water restrictions.
Lilly pill leads to 7.9% weight loss at 40 weeks in trial
Eli Lilly said on Thursday its experimental pill, orforglipron, led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial.
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body weight and showed safety on par with popular injections on the market, with some results coming in line with Wall Street's expectations.
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?
Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.
ChatGPT reveals two stocks to buy with $1,400 IRS payment
Some of us might be due for a windfall in the form of a $1,400 IRS payment. Today is Tax Day, and on top of that, the last day that you can apply to claim a recovery rebate credit for 2021.
Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near
Eli Lilly has shown strong financial performance, driven by key drugs like Mounjaro and Zepbound, but shares remain expensive relative to peers, justifying a 'hold' rating. Revenue, profits, and cash flows have significantly increased, with notable contributions from weight loss and oncology drugs, yet the stock price remains high. Management's investments in expanding the company's footprint and promising drug pipeline, including Retatrutide, indicate potential for future growth.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Hims' Weight Loss Expansion: Real Growth or Just Hype?
One of the more hotly debated stocks in the market, Hims & Hers Health NYSE: HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly's NYSE: LLY blockbuster weight loss drug.
